anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a method for diagnosing autism spectrum disorder by combining a weight learning network. The weight learning network is used for representing the similarity of non-imaging data in potential space, a new method is provided for constructing the edge weights of the population graph, and the definition of the potential space rather than the input space is beneficial and robust to the association. The invention provides a residual connection mode of a graph convolution neural network, and the problems of gradient disappearance and gradient explosion are avoided by introducing a residual unit to relieve information loss caused by convolution operation. Meanwhile, the edge drop strategy can enable node connection to be sparse by randomly deleting edges in the original graph, and the problem of overfitting and overcomplete of deep GCN in the training process can be relieved by introducing the edge drop strategy. Experiments show that the application of the data enhancement algorithm can improve the accuracy of the model, and the feature extraction and classification effects are high. The deep GCN classification method combined with the weight learning network can accurately identify autism spectrum disorders and has good model performance.
Each subject will complete Screening, Baseline, Treatment, and Follow-Up Phases. The Screening Phase will be conducted on an outpatient basis within 30 days, but no less than 3 days, prior to the start of the Baseline Phase. The Baseline Phase will consist of clinical research unit (CRU) admission and final qualification assessments. The Treatment Phase will be comprised of dosing on Day 1, post-treatment safety and pharmacodynamic assessments, and blood and urine collection. Subjects may be discharged approximately 24 hours after study drug administration on Day 2, provided the Modified Aldrete Score and all designated discharge criteria are clinically acceptable to the Investigator. The Follow-Up Phase will occur on Study Day 5 (± 1 day).
Psycho-education (PE) (plus homework) + 4 x Exposure (EX) (plus homework): 20 participants will receive four exposure group sessions after the psycho-education session. In the four sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
PURPOSE:To provide a highly stable hypoglycemic agent containing a specific dihydrochalcone derivative as an active component, exhibiting the increasing action on urine sugar and the reducing action on blood sugar, which are attributed to the inhibition of sugar reabsorption at a kidney and useful as a treating and prophylactic agent for diabetes, etc. CONSTITUTION:A mixture of 2'-O-(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)-6'- hydroxyacetophenone, p-ethoxybenzaldehyde and ethanol is incorporated with 50% aqueous solution of potassium hydroxide dropwise under stirring and the mixture is further stirred over night at a room temperature. The solvent is removed from the reaction mixture under reduced pressure. The residue is incorporated with water and diethyl ether and stirred and the water layer is separated. After the neutralization, the water layer is extracted with ethyl acetate. The extract is subjected to catalytic hydrogenation with a vanadium- carbon catalyst in ethanol and the reaction product is purified by silica gel chromatography to obtain a dihydrochalcone derivative of formula (R is H, OH or lower alkoxy). Subsequently this, as an active component, is formulated by using a pharmaceutical carrier to obtain the objective hypoglycemic agent.
Written exposure therapy (Sloan et al., 2012) is a brief evidence-based treatment for PTSD (US Dept. of VA \& DoD, 2017), wherein patients are asked to write about their trauma memories for 30 minutes, with therapist instruction and feedback before and after each writing exercise.
Patients receive taselisib 4 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The present invention relates to a medicine used for curing face acarodermatitis of people and the preparation method thereof, in particular to rosacea and acne. The medicine is characterized in that the medicine is prepared in the following method that: medical silicon cream is put into a vessel with heating and stirring devices, and then the medical silicon cream is heated and stirred at the temperature ranging from 39 to 45 DEG C and a stirring rate ranging from 50 to 70r/m. Mentha camphor, zinc oxide, boric acid, sublimed sulfur, salicylic acid, fructus bruceae oil, laurus azone, alum glycerite are put into the vessel filled with silicon cream in turn. Then the materials are mixed and stirred. After the materials are even, the materials are put into a muller for grinding. After an even stirring, the powder is put into an emulsification pot and emulsified into delicate ointment. The weight ratio of the medical silicon cream to the mentha camphor to the zinc oxide to the boric acid to the sublimed sulfur to the salicylic acid to the fructus bruceae oil to the laurus azone to the alum glycerite ranges from: 68:1.5:6.5:1.5:6.5:0.5:0.5:3.5 to 78: 2.7: 7.6: 2.7: 7.6: 1.8: 1.5:0.5:5.2.
<P>PROBLEM TO BE SOLVED: To provide a new protein Synoviolin and a gene encoding the Synoviolin.  <P>SOLUTION: The present invention provides a polynucleotide encoding a protein having a specific amino acid sequence. The protein is expressed specifically by synovial membrane tissue and also accompanies the presence of an auto-antibody that recognizes this protein in rheumatoid arthritis (RA) patients. The protein and its antibody can be expected to be used as specific diagnostic markers for RA. In addition, the gene or protein according to the present invention may be used to permit the screening of drugs to treat RA. Moreover, the present invention provides Synoviolin gene transgenic animals. The transgenic animals can be used as RA model animals in the development of pharmaceuticals to treat RA.  <P>COPYRIGHT: (C)2007,JPO&INPIT
A decision support system and method for optimizing medication dosages includes comprehensive patient databases correlating medications and exposure values across data models having pharmacokinetic and pharmacodynamic dimensions. The system determines distinctions between expected and detected medications and exposure values for a patient, and further distinguishes between non-compliant patients from compliant patients having high metabolizing characteristics with respect to certain expected but undetected medications. The system links to and reconciles the patient medical record accordingly. Graphical user interfaces display recommended dosages and projected exposure ranges for the expected and detected medications. In an embodiment, the interface presents certain alternative treatment options determined as being available with respect to the expected but undetected medications. The user in an embodiment may manipulate or select respective nominal dosage values or alternative treatment options, wherein projected exposure values are dynamically calculated and displayed for each of the medications.
INTRODUCTION: The Greenlandic population has one of the world's highest prevalence of otitis media (OM). Approximately 9-14% of all children suffer from OM during childhood. Due to the climate, lack of infrastructure, and minimal access to specialist services, the Greenlandic healthcare system operates under significant challenges. To support treatment implementation, we explored parental experiences of having a child with recurrent acute otitis media (rAOM) and chronic suppurative otitis media in Greenland (CSOM).
METHODS: We applied a qualitative methodology with semi-structured interviews, to investigate parents' individual experiences. We included parents from six selected towns and settlements in Greenland, who were primary caregivers to minimum one child who had suffered from rAOM or CSOM. The interviews followed a semi-structured interview guide.
RESULTS: Eight interviews were conducted with ten parents (nine mothers, one father) to 13 children (nine girls, four boys) aged two to 20 years (median age five years). We carried out a hermeneutic-phenomenological, Ricoeur-inspired text analysis of data. The first episode of OM was associated with uncertainty about the condition, including pain relief and treatment. However, recurrence led to symptom recognition and a changed disease perception among the parents: from being a simple case of childhood OM to a recognition of a chronic condition that might lead to delayed linguistic development and hearing impairment.
CONCLUSION: Under difficult healthcare situations, parents represented a unique resource in care and treatment implementation. Parents often feel alone with the responsibility of care and had concerns for their child's hearing and language development, and they wished for their experiences and observations to be actively included in consultations.
1,141,573. Medicinal polysaccharides. E. YAMADA and H. YAMADA. 29 March, 1967, No. 14290/67. Heading ASB [Also in Division C3] A polysaccharide (claimed per se) containing N-containing glycosides and having the I-R spectrum shown in Fig. 1 is extracted from green alga by successive extraction with water, an aqueous alkaline solution, and an aqueous acidic solution, removing impurities such as protein, organic acids, tannic matter and colouring matter by adding to each extract lead acetate, removing the resulting precipitate, adding ethanol to each of the purified extracts to form precipitates and recovering these precipitates. Specified algae are clorella or scenedesmus. The product is of use in stimulating activity of the reticulo - endothelial system. In an example a rat is injected with a polysaccharide as above and the increased rate of removal of carbon particles previously injected into the blood stream is noted. (See Figs. 2 and 3, not reproduced).
A proper process is used to obtain the active Fab' fragment of the monoclonal antibody 3A5 of human liver cancer cell BEL-7402. The glucosan T-40 is used as medium to couple Fab' with Pingyangmycin. The conjugate has killing action to human liver cancer cell BEL-7402 and oral cancer cell KB for the external experiment. For the internal experiment, colon cancer, tissue is homogenized by physiologic saline and then grafted to Balb/c mouse and the medicine is applied after 24 hrs. Its tumor suppression rate is 77-91%. The survival time of animal is elongated obviously. Its curative effect is prior to the Pingyang mycin.
Pro-drug chemotherapy is an approach to cancer treatment that is being investigated as a means to achieve higher concentrations of cytotoxic or biologically active agents at a tumor location while avoiding systemic toxicity. With pro-drug chemotherapy, a relatively non-toxic form of a cytotoxin, the pro-drug, is converted into the active cytotoxic agent at the tumor site or other specific location. G-202 (mipsagargin) is a thapsigargin pro-drug; it consists of a cytotoxic analog of thapsigargin coupled to a masking peptide which inhibits its biologic activity until proteolytic cleavage at the tumor site. Thapsigargin is a natural product with profound effects on cell viability. Thapsigargin is a non-cell-type specific toxin with documented ability to kill a broad spectrum of cancer cell lines as well as normal endothelial cells, fibroblasts and osteoblasts. It induces a rapid and pronounced increase in the concentration of cytosolic calcium, due to blockade of the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump to which it binds with high affinity. The increase in cytosolic calcium leads to induction of apoptosis and ensuing cell death.

The anti-tumor effect of G-202 in humans with advanced solid tumors is not yet known.
Parents in the experimental group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the experimental intervention includes parent-child sexual health communication and HPV vaccination navigation.
Resonance Raman scatter is used to differentiate in quasi-real time (QRT) anomalous tissue from adjacent normal tissue. The fingerprint generated from the tissue by a 1 second pulse of 532 nm emission for approximately one second is collected and is relayed by fiber-optic to a computerized controller that determines whether the target tissue is anomalous or normal. If anomalous it is ablated. This is performed by a pattern of Resonance Raman diagnostic emission and diagnostic sensor fibers. This diagnostic/therapeutic pattern of fibers can be moved by a joystick or robotically controlled. The data received by the computer is examined instantly, and should the site be diagnosed as anomalous, the optical biopsy/ablation is repeated immediately and repeated until the site is read as normal. Novel arrays of the diagnostic and therapeutic energies ensure a 3D anomalous tissue free zone around the removal site.
Since JNS013 is a combination of tramadol hydrochloride (TRAM) acting as a weak opioid with acetaminophen (APAP) inhibiting central COX-3, it is expected to have an intermediate effect between narcotic analgesics and NSAIDs (non-steroid anti-inflammatory drugs). This is a multicenter, open-label, dose response study. The purpose of this study is to find the clinical dose range of TRAM in patients with chronic pain due to osteoarthritis (OA) of the knee or low back pain (LBP) who cannot attain a sufficient analgesic effect from NSAIDs. The investigational product will be orally administered 4 times daily (after each meal and before bedtime) at a dose of 25 to 100 mg at least 4-hour intervals. Treatment will be started at an initial dose of 100 mg/day, and the dose is titrated by 25 mg every 7 days if the analgesic effect is insufficient and there is no problem with the safety. Treatment will be continued up to 35 days in total at a dose of 400 mg/day or a dose of which a sufficient analgesic effect can be obtained. The primary efficacy endpoint is the change in the intensity of pain from the beginning of dose-finding period (baseline) to the final assessment point (Up to Day 36), by using VAS (Visual Analog Scale). The safety evaluations are adverse events, laboratory examinations, blood pressure/pulse rate and body weight. Total study period of this study is 49days, Screening period is 7days, Administration period is 35 days and Follow-up period is 7 days. The investigational product will be orally administered 4 times daily (after each meal and before bedtime) at a dose of 25 to 100 mg at least 4-hour intervals. Treatment will be started at an initial dose of 100 mg/day, and the dose is titrated by 25 mg every 7 days if the analgesic effect is insufficient and there is no problem with the safety. Treatment will be continued up to 35 days in total at a dose of 400 mg/day or a dose of which a sufficient analgesic effect can be obtained.
Cognitive impairment is a major complication of cerebral ischemia-reperfusion (CIR) injury and has an important impact on the quality of life of patients. However, the precise mechanisms underlying cognitive impairment after CIR injury remain elusive. In the current study, we investigated the role of interleukin 17 A (IL-17A) on CIR injury-induced cognitive impairment in wild-type and IL-17A knockout mice using RNA sequencing analysis, neurological assessments, Golgi-Cox staining, dendritic spine analysis, immunofluorescence assay, and western blot analysis. RNA sequencing identified 195 CIR-induced differentially expressed genes (83 upregulated and 112 downregulated), highlighting several enriched biological processes (negative regulation of phosphorylation, transcription regulator complex, and receptor ligand activity) and signaling pathways (mitogen-activated protein kinase [MAPK], tumor necrosis factor, and IL-17 signaling pathways). We also injected adeno-associated virus into the bilateral hippocampal CA1 regions of CIR mice to upregulate or downregulate cyclic AMP response element-binding protein. IL-17A knockout activated the extracellular signal-regulated kinase (ERK)/MAPK signaling pathway and further improved synaptic plasticity, structure, and function in CIR mice. Together, our findings suggest that IL-17A deficiency alleviates CIR injury by activating the ERK/MAPK signaling pathway and enhancing hippocampal synaptic plasticity.
LIVMARLI contains propylene glycol. Patients less than 5 years of age are at highest risk for propylene glycol toxicity, and a safe level for propylene glycol exposure with repeated administration has not been established for pediatric patients less than 5 years of age. When LIVMARLI is administered at the dose (380 mcg/kg once daily) for treatment of cholestatic pruritus in patients with ALGS, the exposure to propylene glycol will be 14.6 mg/kg/day. When LIVMARLI is administered at the dose (570 mcg/kg twice daily) for treatment of cholestatic pruritus in patients with PFIC, the exposure to propylene glycol will be 21.9 mg/kg/day. The total daily intake of propylene glycol from all sources should be considered for managing the risk of propylene glycol toxicity.

Monitor patients for signs of potential propylene glycol toxicity, including hemolysis, hyperosmolarity with anion gap metabolic acidosis, acute kidney injury, and CNS toxicity. Discontinue LIVMARLI if propylene glycol toxicity is suspected [see Overdosage (10)].
FIELD: medicine, traumatology, orthopedics. SUBSTANCE: invention can be used in endoprosthesis of large articulations using methylmethacrylate-base osseous cement. For this purpose, 24 h before operation rheopolyglucinum in the dose 5-6 ml/kg in combination with 200 mg of trental is administrated intravenously for 60-90 min; 12 h before operation fraxiparine is administrated in the dose 0.3 ml subcutaneously. Reambirinum 1.5% solution in the dose 5-6 ml/kg is administrated intravenously 1 h before application of osseous cement with infusion period for 60-90 min; 2 min before application of osseous cement prednisolone in the dose 1 mg/kg and 2 mg of tavegil are administrated intravenously. In post-operative period rheopolyglucinum in the dose 5-6 ml/kg and 200 mg of trental are administrated for 60-90 min for 3 days intravenously; fraxiparine in the dose 0.3 ml is administrated for 7 days subcutaneously; reambirinum 1.5% solution in the dose 5-6 ml/kg is administrated for 60-90 min for 3 days intravenously. Method provides reducing thrombotic and embolic complications associated with toxic effect of methylmethacrylate and infectious complications also. EFFECT: improved prophylaxis method. 1 ex
PURPOSE:To provide the titled material for the continuous administration of drug through the skin or mucosa and composed of a composition obtained by clathrating a liquid transcutaneous absorbefacient in cyclodextrin or its derivative and dispersing the obtained compound in a drug-containing polymeric compound. CONSTITUTION:A liquid absorbefacient (e.g. methyloctylsulfoxide, dimethyllaurylamide, etc.) is clathrated in cyclodextrin or its derivative, and the obtained compound is dispersed in a drug-containing polymeric compound [e.g. a polymeric compound free of pressure-sensitive adhesivity under normal condition such as soft polyvinyl chloride, polyolefin, etc., or a polymeric compound having pressure-sensitive adhesivity under normal condition such as n- butyl (meth)acrylate, etc.] to obtain the objective medical material for external use. The above drug is e.g. a corticosteroid such as hydrocortisone, an analgesic and anti-inflammatory agent such as acetaminophenone, etc., a narcotic sedative such as phenobarbital, etc.
Arthrobacter phenantherivorans L131 strain for antagonizing respiratory pathogenic bacteria and application thereof are provided. The strain is preserved in Guangdong province microorganism strain preservation center in 2019, 10 and 08 days, and the preservation numbers are as follows: GDMCC No: 60800. the 16S rDNA sequence of the strain is shown in SEQ ID NO: 1 is shown. Application of Arthrobacter phenantherivorans L131 strain or fermentation supernatant thereof in preparation of medicament for antagonizing respiratory pathogenic bacteria. Meanwhile, the Arthrobacter phenantivorans L131 strain fermentation supernatant can be used for further preparing the treatment medicine for respiratory tract infection by utilizing the characteristic of efficiently antagonizing respiratory tract pathogenic bacteria. Also provides a medicament for antagonizing respiratory pathogens or treating respiratory infections, which comprises a fermentation supernatant of the L131 strain. The fermentation supernatant of the Arthrobacter phenantivorans L131 strain can efficiently antagonize respiratory pathogenic bacteria, can be used for preparing medicaments for antagonizing the respiratory pathogenic bacteria or treating respiratory infection, and has a wide application prospect.
The invention provides a traditional Chinese medicinal preparation for treating a stable phase chronic obstructive pulmonary disease. The traditional Chinese medicinal preparation is prepared from the following medicinal materials in part by weight: 10 to 20 parts of medlar, 3 to 5 parts of prepared common monkshood daughter root, 3 to 5 parts of cinnamon, 10 to 20 parts of malaytea scurfpea fruit, 10 to 20 parts of south dodder seed, 10 to 20 parts of epimedium, 10 to 20 parts of Chinese angelica, 10 to 20 parts of red paeony root, 10 to 20 parts of szechuan lovage rhizome, 10 to 20 parts of root of rehmannia, 10 to 20 parts of amur corktree bark, 10 to 20 parts of white mulberry root bark, 20 to 30 parts of astragalus, 5 to 10 parts of liquoric root, 10 to 20 parts of aster, 5 to 10 parts of dried ginger, 5 to 10 parts of fritillary and 5 to 10 parts of peeled ginkgo seed. The traditional Chinese medicinal preparation can be prepared into formulations such as capsule preparations, granules, tablets, pills, oral liquid preparations and the like. The traditional Chinese medicinal preparation is a pure traditional Chinese medicinal preparation and does not have toxic or side effect. When the medicaments are used together, the traditional Chinese medicinal preparation has the effects of tonifying qi, nourishing yin, warming yang, supplementing lung, invigorating the spleen, nourishing kidney, relieving cough and asthma, eliminating phlegm, and treating both the symptoms and diseases. The traditional Chinese medicinal preparation has the obvious effect of treating the stable-phase chronic obstructive pulmonary disease and has the effect of treating diseases such as bronchial asthma and the like.
PURPOSE: To obtain a preparation for external use excellent in beautifying and whitening effects on the skin and humectant effects on the skin and hair. CONSTITUTION: This preparation for external use contains 0.0001-30wt.%, preferably 0.1-5wt.% neoagarobiose which is one of heterobioses. The neoagarobiose has high suppressing actions on melanogenesis and is excellent humectant actions. The neoagarobiose is further suitably blended with ingredients usually used in cosmetics, quasi-drugs or medicines and a well-known medicine, as necessary, can be added thereto to prepare the neoagarobiose into a skin-care cosmetic, a makeup cosmetic, a detergent, a cosmetic for hair and a dermal preparation for external use. The neoagarobiose is obtained by culturing Alteromonas sp. E-1 which is one of microorganisms capable of producing an agar hydrolase, providing the agar hydrolase, then hydrolyzing agar or agarose therewith and cooling and freeze-drying the resultant hydrolyzate.